Phaseline

Targets › DNA

DNA: drug programs, companies and trials

28 programs from 25 companies in 42 trials: 22 Phase 2, 14 Phase 3, 6 Phase 1; Oncology, Infectious disease; next expected readout Nov 2026.

Open in Phaseline: the race on DNA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sun Yat-sen Universitycarboplatin
DNA-alkylating platinum agent that forms covalent DNA adducts
DNAPhase 3Retinoblastoma; Resectable Mucosal MelanomaMar 2027
Henan Cancer HospitalCarboplatin
Platinum-based chemotherapy; DNA crosslinking agent
DNAPhase 3Esophageal Squamous Cell Carcinoma; Esophageal Malignant Neoplasm PrimaryDec 2027
SymBio PharmaceuticalsBrincidofovir
DNA polymerase inhibitor
DNAPhase 3Adenovirus Infections; Progressive Multifocal LeukoencephalopathyJan 2028
Fondazione Italiana Linfomi - ETSObinutuzumab-bendamustine (G-Benda)
glycoengineered anti-CD20 monoclonal antibody combined with alkylating agent bendamustine
CD20, DNAPhase 3Follicular LymphomaJul 2028
Fondazione Italiana Linfomi - ETSRituximab-bendamustine (R-Benda)
anti-CD20 monoclonal antibody combined with alkylating agent bendamustine
CD20, DNAPhase 3Follicular LymphomaJul 2028
Henan Cancer HospitalCisplatin
DNA crosslinking agent
DNAPhase 3Esophageal Squamous Cell CarcinomaDec 2028
Vastra Gotaland RegionMelphalan
Alkylating agent delivered via hepatic perfusion
DNAPhase 3Uveal MelanomaDec 2028
Binkui LiOxaliplatin
Platinum-based chemotherapy (DNA cross-linking agent)
DNAPhase 3Hepatocellular CarcinomaMay 2030
Children's Oncology GroupDactinomycin
Antineoplastic antibiotic; DNA intercalating agent
DNAPhase 3Embryonal Rhabdomyosarcoma; Stage I Mixed Cell Type Kidney Wilms Tumor; RhabdomyosarcomaJun 2030
Kyung Hee University Hospital at GangdongOxaliplatin
Platinum-based alkylating agent; DNA crosslinker
DNAPhase 3Rectal Cancer–
European Organisation for Research and Treatment of Cancer - EORTCmechlorethamine hydrochloride
Nitrogen mustard; alkylating agent
DNAPhase 3Lymphoma–
Memorial Sloan Kettering Cancer CenterCaptisol Enabled Melphalan
Nitrogen mustard alkylating agent (melphalan formulation with Captisol)
DNAPhase 2Sarcoma; Multiple Myeloma; Lymphoma; Hematologic MalignanciesNov 2026
Shanghai Jiao Tong University School of MedicineSatraplatin
Platinum-based alkylating agent; forms DNA cross-links
DNAPhase 2Prostate Cancer PatientsDec 2026
National Cancer Institute, NaplesTemozolomide
Alkylating agent causing DNA methylation
DNAPhase 2Lung Neuroendocrine NeoplasmDec 2026
Hebei Medical University Fourth HospitalCisplatin
Platinum-based alkylating agent; DNA cross-linker
DNAPhase 2Esophageal Squamous Cell CarcinomaDec 2026
The Second Affiliated Hospital of Fujian Medical UniversityOxaliplatin
Third-generation platinum agent causing DNA cross-linking
DNAPhase 2Stomach NeoplasmsDec 2026
Shanghai Jiao Tong University School of Medicinecisplatin
DNA alkylating agent, platinum compound
DNAPhase 2Neoplasm NeckJan 2027
Tianjin Medical University General HospitalTemozolomide
Alkylating agent
DNAPhase 2Glioblastoma, IDH-wildtypeFeb 2027
Université de SherbrookeIA Carboplatin + IA Caelyx
Carboplatin (platinum-based alkylating agent) combined with liposomal doxorubicin (anthrac
DNAPhase 2Glioblastoma MultiformeApr 2027
Changhai HospitalCisplatin
Platinum-based alkylating agent that cross-links DNA strands
DNAPhase 2Neoadjuvant TherapyAug 2027
Shanghai Chest HospitalCarboplatin
Platinum-based alkylating agent; DNA crosslinking
DNAPhase 2Non-squamous NSCLCDec 2027
Fifth Affiliated Hospital, Sun Yat-Sen UniversityTemozolomide
Alkylating agent
DNAPhase 2Recurrent GlioblastomaDec 2027
M.D. Anderson Cancer CenterCisplatin
Platinum-based DNA cross-linking agent
DNAPhase 2Head and Neck Squamous Cell CarcinomaDec 2027
Tianjin Medical University Cancer Institute and HospitalTemozolomide
Alkylating agent
DNAPhase 2Neuroblastoma (NB)Dec 2028
Institut CurieVP16, carboplatin
Platinum-based alkylating agent + thermal laser therapy (chemothermotherapy)
DNAPhase 2RetinoblastomaJan 2035
Oslo University HospitalOxaliplatine
DNA-crosslinking alkylating agent
DNAPhase 2Pancreatic Cancer–
Emory UniversityTemozolomide
Alkylating agent
DNAPhase 1NeuroblastomaDec 2026
Haukeland University HospitalTemozolomide
DNA alkylating agent
DNAPhase 1GlioblastomaDec 2026

Conditions

Lymphoma (4) Retinoblastoma (4) Esophageal Squamous Cell Carcinoma (3) Sarcoma (2) Multiple Myeloma (2) Follicular Lymphoma (2) Glioblastoma Multiforme (1) Esophageal Malignant Neoplasm Primary (1) Hematologic Malignancies (1) Rectal Cancer (1) Prostate Cancer Patients (1) Glioblastoma (1)

Modalities

small molecule (11), mixed (7), antibody (3), other (2), protein or peptide (2)

Companies

Henan Cancer Hospital (2) Shanghai Jiao Tong University School of Medicine (2) Fondazione Italiana Linfomi - ETS (2) Université de Sherbrooke (1) Memorial Sloan Kettering Cancer Center (1) Kyung Hee University Hospital at Gangdong (1) Haukeland University Hospital (1) Children's Oncology Group (1) Shanghai Chest Hospital (1) Sun Yat-sen University (1) Institut Curie (1) Tianjin Medical University Cancer Institute and Hospital (1) Oslo University Hospital (1) Vastra Gotaland Region (1) Hebei Medical University Fourth Hospital (1) Emory University (1) Tianjin Medical University General Hospital (1) The Second Affiliated Hospital of Fujian Medical University (1) European Organisation for Research and Treatment of Cancer - EORTC (1) M.D. Anderson Cancer Center (1)

Related targets

CD20 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.